Ouabain prevents pathological cardiac hypertrophy and heart failure through activation of phosphoinositide 3-kinase α in mouse

Table 1 Echocardiographic analysis (baseline) of Con and p85-KO mouse hearts

	BW (g)	HR (bpm)	EDA (cm²)	ESA (cm²)	PWT (cm)	SWT (cm)	RWT	MPI	FS	LV mass (g)
Con	31.8 ± 1.2	439 ± 9	0.168 ± 0.004	0.088 ± 0.003	0.114 ± 0.003	0.104 ± 0.003	0.60 ± 0.02	0.36 ± 0.03	0.45 ± 0.02	0.126 ± 0.004
KO	28.4 ± 1.0	438 ± 11	0.153 ± 0.004*	0.081 ± 0.004	0.108 ± 0.005	0.087 ± 0.002*	0.54 ± 0.02	0.30 ± 0.02	0.45 ± 0.01	0.105 ± 0.005*

The p85-KO and the Cre controls (12–16 week-old, male) were subjected to echocardiography analysis
BW body weight; HR heart rate; EDA end diastolic area; ESA end systolic area; PWT posterior wall thickness; SWT septal wall thickness; RWT relative wall thickness; MPI myocardial performance index; FS fractioning shortening; LV mass left ventricular mass; Con n = 21; KO n = 15
* p < 0.05 v.s. Con